Ximelagatran: Pharmacology, pharmacokinetics, and pharmacodynamics

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Thromboembolism is the largest cause of morbidity and mortality in the western world, yet oral anticoagulation is currently available only with vitamin K antagonists - most often, warfarin. Warfarin has been used for treatment of thrombotic disease for about 50 years. However, despite its widespread use, it is associated with several limitations, such as varied patient response, a narrow therapeutic window, numerous drug and food interactions, and need for frequent therapeutic monitoring. In addition, its full anticoagulant effect usually takes at least 4-5 days after the start of therapy or any dosage change, and it has a slow offset of therapy. A new oral anticoagulant, ximelagatran, has considerable advantages compared with warfarin. The agent requires no therapeutic monitoring, has a wide therapeutic window, and is not known to interact with food or drugs. The advantages ximelagatran brings to clinical practice should be a welcome addition to the options for management of thrombotic disease.

Original languageEnglish (US)
Pages (from-to)169S-178S
JournalPharmacotherapy
Volume24
Issue number10 I
DOIs
StatePublished - Oct 1 2004

Fingerprint

Pharmacokinetics
Pharmacology
Warfarin
Anticoagulants
Therapeutics
Food-Drug Interactions
Western World
Vitamin K
Thromboembolism
Disease Management
ximelagatran
Morbidity
Food
Mortality
Pharmaceutical Preparations

Keywords

  • Pharmacodynamics
  • Pharmacokinetics
  • Pharmacology
  • Thromboembolism
  • Venous thromboembolic disease
  • Warfarin
  • Ximelagatran

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Ximelagatran : Pharmacology, pharmacokinetics, and pharmacodynamics. / Dobesh, Paul P.

In: Pharmacotherapy, Vol. 24, No. 10 I, 01.10.2004, p. 169S-178S.

Research output: Contribution to journalReview article

@article{da4ea16833944020b03b89448b951096,
title = "Ximelagatran: Pharmacology, pharmacokinetics, and pharmacodynamics",
abstract = "Thromboembolism is the largest cause of morbidity and mortality in the western world, yet oral anticoagulation is currently available only with vitamin K antagonists - most often, warfarin. Warfarin has been used for treatment of thrombotic disease for about 50 years. However, despite its widespread use, it is associated with several limitations, such as varied patient response, a narrow therapeutic window, numerous drug and food interactions, and need for frequent therapeutic monitoring. In addition, its full anticoagulant effect usually takes at least 4-5 days after the start of therapy or any dosage change, and it has a slow offset of therapy. A new oral anticoagulant, ximelagatran, has considerable advantages compared with warfarin. The agent requires no therapeutic monitoring, has a wide therapeutic window, and is not known to interact with food or drugs. The advantages ximelagatran brings to clinical practice should be a welcome addition to the options for management of thrombotic disease.",
keywords = "Pharmacodynamics, Pharmacokinetics, Pharmacology, Thromboembolism, Venous thromboembolic disease, Warfarin, Ximelagatran",
author = "Dobesh, {Paul P.}",
year = "2004",
month = "10",
day = "1",
doi = "10.1592/phco.24.15.169S.43160",
language = "English (US)",
volume = "24",
pages = "169S--178S",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "10 I",

}

TY - JOUR

T1 - Ximelagatran

T2 - Pharmacology, pharmacokinetics, and pharmacodynamics

AU - Dobesh, Paul P.

PY - 2004/10/1

Y1 - 2004/10/1

N2 - Thromboembolism is the largest cause of morbidity and mortality in the western world, yet oral anticoagulation is currently available only with vitamin K antagonists - most often, warfarin. Warfarin has been used for treatment of thrombotic disease for about 50 years. However, despite its widespread use, it is associated with several limitations, such as varied patient response, a narrow therapeutic window, numerous drug and food interactions, and need for frequent therapeutic monitoring. In addition, its full anticoagulant effect usually takes at least 4-5 days after the start of therapy or any dosage change, and it has a slow offset of therapy. A new oral anticoagulant, ximelagatran, has considerable advantages compared with warfarin. The agent requires no therapeutic monitoring, has a wide therapeutic window, and is not known to interact with food or drugs. The advantages ximelagatran brings to clinical practice should be a welcome addition to the options for management of thrombotic disease.

AB - Thromboembolism is the largest cause of morbidity and mortality in the western world, yet oral anticoagulation is currently available only with vitamin K antagonists - most often, warfarin. Warfarin has been used for treatment of thrombotic disease for about 50 years. However, despite its widespread use, it is associated with several limitations, such as varied patient response, a narrow therapeutic window, numerous drug and food interactions, and need for frequent therapeutic monitoring. In addition, its full anticoagulant effect usually takes at least 4-5 days after the start of therapy or any dosage change, and it has a slow offset of therapy. A new oral anticoagulant, ximelagatran, has considerable advantages compared with warfarin. The agent requires no therapeutic monitoring, has a wide therapeutic window, and is not known to interact with food or drugs. The advantages ximelagatran brings to clinical practice should be a welcome addition to the options for management of thrombotic disease.

KW - Pharmacodynamics

KW - Pharmacokinetics

KW - Pharmacology

KW - Thromboembolism

KW - Venous thromboembolic disease

KW - Warfarin

KW - Ximelagatran

UR - http://www.scopus.com/inward/record.url?scp=4644327496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644327496&partnerID=8YFLogxK

U2 - 10.1592/phco.24.15.169S.43160

DO - 10.1592/phco.24.15.169S.43160

M3 - Review article

C2 - 15624336

AN - SCOPUS:4644327496

VL - 24

SP - 169S-178S

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 10 I

ER -